diff --git a/src/data/drug-data.tsx b/src/data/drug-data.tsx
index 3be90a4696cf4e2413d6a95b1bce1d7bf656df22..203f9fa632d2b06677089be3c17c3ea1688652be 100644
--- a/src/data/drug-data.tsx
+++ b/src/data/drug-data.tsx
@@ -4,7 +4,7 @@ export interface DrugDatensatz {
     picture: string; 
     introduction: string;
     examples: Array<example>; 
-    
+
 
 }
 
@@ -37,7 +37,7 @@ export const drugdata: (Array<DrugDatensatz>)  = [
         examples: [
             {
                 title: "Trikafta", //quelle 4
-                text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor","Indications: For CF patients aged 2 years and older with at least one F508del mutation à 85 % of CF patients","Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5].","Administration: Oral tablets","Approval: Approved by the EMA in 2020 "]
+                text: ["Active ingredient(s): Combination of elexacaftor/tezacaftor/ivacaftor","Indications: For CF patients aged 2 years and older with at least one F508del mutation = 85 % of CF patients","Mechanism: Elexacaftor and tezacaftor act as correctors on misfolded CFTR and permit delivery to the cell surface, thereby improving the channel density at the plasma membrane, while ivacaftor as a potentiator acts on CFTR channels that have reached the cell surface and increase the gating and conductance of ions [5].","Administration: Oral tablets","Approval: Approved by the EMA in 2020 "]
             },
             {
                 title: "Symdeko", //quelle 1